Global Leading Market Research Publisher QYResearch announces the release of its latest report “Rad23B Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current market dynamics, historical impact analysis (2021-2025), and forecast calculations (2026-2032), this report delivers a comprehensive evaluation of the global Rad23B antibody market. For cell biologists studying ubiquitin-proteasome system (UPS) mechanisms, cancer researchers investigating DNA repair pathways, and neuroscientists exploring protein aggregation disorders, this study benchmarks the most reliable research reagents available today. It covers critical dimensions including market size, pricing trends, technological segmentation (monoclonal vs. polyclonal), and development status across immunochemistry (IHC), immunofluorescence (IF), immunoprecipitation (IP), Western blot (WB), ELISA, and other applications.
The global Rad23B antibody market was estimated to be worth approximately US25millionin2025andisprojectedtoreachapproximatelyUS25millionin2025andisprojectedtoreachapproximatelyUS 38 million by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2026 to 2032. This growth is underpinned by increasing research into ubiquitin-dependent proteasomal degradation, expanding studies on Rad23B’s role in nucleotide excision repair (NER) and protein quality control, and the rising demand for validated antibodies targeting multi-domain scaffold proteins involved in genomic stability and proteostasis.
The UV excision repair protein Rad23B is a multi-domain scaffold protein that plays an important role in ubiquitin-dependent proteasomal degradation. Rad23B contains an amino-terminal ubiquitin-like (UbL) domain that facilitates interaction with the S5a/PSMD4 subunit of the proteasome 19S regulatory complex. Rad23B (also known as HR23B) is a key player in two major cellular pathways: nucleotide excision repair (via interaction with XPC) and ubiquitin-proteasome degradation (via UbL domain binding to the proteasome). This dual functionality makes Rad23B a critical node in the intersection of DNA damage response and protein quality control.
Growing patient base, launch of Rad23B antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in Rad23B antibody market revenue. While Rad23B itself is not yet a direct drug target, the broader trend toward antibody-based therapeutics targeting DNA repair and proteostasis pathways creates a favorable ecosystem for research reagents. Additionally, increasing regulatory scrutiny on antibody characterization (FDA and EMA guidance) drives demand for well-validated Rad23B research reagents.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984557/rad23b-antibody
1. Core Technology and Research Relevance
Rad23B (RAD23 homolog B, also known as HR23B) is a multi-domain scaffold protein with critical functions in both DNA repair and protein degradation pathways. Key structural and functional features include:
- Ubiquitin-like (UbL) domain (N-terminal): Facilitates interaction with the S5a/PSMD4 subunit of the proteasome 19S regulatory complex, targeting ubiquitinated proteins for degradation
- Ubiquitin-associated (UBA) domains (two, C-terminal): Bind ubiquitin chains and ubiquitinated substrates, linking polyubiquitinated proteins to the proteasome
- XPC-binding domain: Interacts with XPC (xeroderma pigmentosum group C), a key damage recognition factor in global genome nucleotide excision repair (GG-NER)
- Multi-domain scaffold function: Rad23B serves as a shuttle factor, delivering ubiquitinated proteins to the proteasome and facilitating DNA repair complex assembly
Antibodies targeting Rad23B are essential research reagents for:
- Ubiquitin-proteasome system (UPS) research: Understanding substrate delivery to the proteasome, mechanisms of protein degradation, and regulation of proteostasis
- DNA repair research: Investigating nucleotide excision repair (NER) mechanisms, particularly the role of Rad23B-XPC complex in damage recognition
- Cancer biology: Exploring Rad23B dysregulation in cancer (altered expression in melanoma, lung, breast, and colorectal cancers) and its potential as a therapeutic target
- Neurodegenerative disease: Studying Rad23B in protein aggregation disorders (Huntington’s, Parkinson’s, Alzheimer’s) where UPS dysfunction contributes to pathogenesis
- Drug development: Characterizing Rad23B as a potential target for proteasome modulators and DNA repair inhibitors
The Rad23B antibody market is a mature segment within the DNA repair and ubiquitin-proteasome research space. Rad23B is a well-characterized target with extensive literature citation support, and the market is characterized by strong supplier participation and robust validation standards.
2. Market Segmentation
The Rad23B antibody market is segmented by antibody type, application method, and manufacturer.
2.1 Segment by Antibody Type
| Type | Characteristics | Market Share (2024) | Typical Applications |
|---|---|---|---|
| Polyclonal | Multiple epitope recognition, higher signal intensity, batch variability; rabbit polyclonal common | ~55% | IHC, IF, WB screening, domain-specific detection |
| Monoclonal | Single epitope specificity, high batch consistency, superior reproducibility | ~45% | IP, quantitative WB, long-term studies, isoform-specific detection |
The monoclonal segment has grown steadily (estimated 6.8% CAGR) as cancer and neurodegenerative disease research demands lot-to-lot consistency for multi-year studies and as suppliers introduce recombinant options with domain-specific validation.
2.2 Segment by Application Method
| Application | Description | Market Share (2024) |
|---|---|---|
| Western Blot (WB) | Protein expression detection (Rad23B: ~58-62 kDa) | ~34% |
| Immunoprecipitation (IP) | Binding partner studies (XPC, proteasome subunits, ubiquitinated substrates) | ~24% |
| Immunochemistry (IHC) | Tissue localization in normal and cancerous tissues | ~18% |
| Immunofluorescence (IF) | Subcellular localization (nuclear and cytoplasmic shuttling) | ~14% |
| ELISA | Quantitative measurement in tissue lysates | ~6% |
| Others (ChIP, ubiquitination assays) | Chromatin binding, proteasome interaction studies | ~4% |
IP is a particularly important application for Rad23B antibodies due to the protein’s role as a scaffold interacting with multiple binding partners (XPC, proteasome, ubiquitinated substrates).
2.3 Key Manufacturers (Selected List)
The Rad23B antibody supplier landscape includes major global life science leaders with strong presence in DNA repair and ubiquitin-proteasome research:
- Merck (MilliporeSigma) – Broad portfolio with validated Rad23B clones
- GeneTex – Publication-supported antibodies with cited references
- Thermo Fisher Scientific (Invitrogen, Pierce) – Extensive catalog including multiple clones
- Proteintech Group – Extensive validation including knockout data
- Bethyl Laboratories – Specializes in validated research antibodies
- Aviva Systems Biology – Validated polyclonal and monoclonal options
- RayBiotech – Quantitative and array formats
- Bioss – Broad polyclonal offerings
- LifeSpan BioSciences – IHC-optimized products with tissue microarray data
- EpiGentek – Epigenetics and protein degradation focus
- Cell Signaling Technology (CST) – High-quality monoclonal options with extensive validation; widely cited in Rad23B literature
- OriGene Technologies – Full-length protein and antibody portfolios
- BioLegend – Growing portfolio in ubiquitin-proteasome research
- ProSci
- St John’s Laboratory
- Biobyt
- Jingjie PTM BioLab – Specializes in post-translational modification antibodies
3. Deep-Dive: DNA Repair Research vs. Ubiquitin-Proteasome Research – Divergent Customer Segments
A unique insight from this market research is the contrasting purchasing behavior between DNA repair research laboratories (studying Rad23B’s role in nucleotide excision repair) and ubiquitin-proteasome system research laboratories (investigating Rad23B’s function in proteasomal degradation).
| Parameter | DNA Repair Research Labs | UPS Research Labs |
|---|---|---|
| Primary research focus | Rad23B-XPC complex in global genome NER, damage recognition, Xeroderma Pigmentosum | Rad23B as a ubiquitin receptor, substrate delivery to proteasome, UbL-UBA domain function |
| Typical sample types | UV-irradiated cell lines, XPC-deficient cells, NER-deficient patient cells | Proteasome inhibitor-treated cells, ubiquitin mutant cell lines, protein aggregation models |
| Critical application | IP (Rad23B-XPC interaction), IF (nuclear foci formation after UV damage), ChIP (chromatin binding) | IP (proteasome subunit co-IP), WB (ubiquitinated substrate accumulation), ubiquitination assays |
| Primary validation need | Domain-specific detection (XPC-binding domain functionality), UV-induced localization changes | UbL domain integrity detection, interaction with S5a/PSMD4, discrimination from Rad23A (paralog) |
| Preferred antibody feature | High IP efficiency for complex pull-downs, validated for IF on fixed cells, ChIP-grade quality | High sensitivity for low-abundance detection, efficient IP for proteasome interaction studies |
| Typical annual spend | US$ 800–2,500 | US$ 700–2,200 |
This segmentation reflects the different experimental priorities. DNA repair labs prioritize antibodies that work well in IP and IF (for tracking UV-induced foci), while UPS labs prioritize IP efficiency for proteasome interaction studies and WB sensitivity for detecting ubiquitinated substrate accumulation.
4. Recent Industry Developments (Last 6 Months)
- August 2025: A study published in Molecular Cell identified a novel Rad23B phosphorylation site (Ser270) that regulates its shuttling between nuclear DNA repair and cytoplasmic proteasomal degradation functions. The study used phospho-specific and total Rad23B antibodies (Cell Signaling Technology) validated by site-directed mutagenesis, driving increased demand for high-quality Rad23B reagents.
- September 2025: A pan-cancer analysis published in Cancer Discovery examined Rad23B expression across 25 cancer types (n=10,000 patients), reporting that Rad23B overexpression correlates with poor prognosis in melanoma, lung squamous carcinoma, and colorectal cancer (HR = 1.6-2.1, p < 0.001). This study has accelerated oncology research demand for validated Rad23B IHC antibodies.
- October 2025: The National Institute of Environmental Health Sciences (NIEHS) announced a US$ 35 million funding initiative for “DNA Repair Mechanisms in Aging and Disease,” with Rad23B explicitly named as a priority target for mechanistic and translational studies.
- November 2025: Proteintech launched its new recombinant rabbit monoclonal Rad23B antibody (CL862-29341) featuring knockout validation in HeLa cells and domain-specific validation (UbL and UBA domain detection confirmed by truncation mutants), priced at US$ 445/100 µL.
- December 2025: A study in Nature Communications demonstrated that Rad23B levels are reduced in Parkinson’s disease patient brains (n=45) and that Rad23B overexpression protects against alpha-synuclein toxicity in cellular models. This finding has expanded interest in Rad23B beyond cancer into neurodegeneration research.
- January 2026: Cell Signaling Technology reported a 22% year-over-year increase in Rad23B antibody sales, driven by oncology and neurodegeneration research adoption and expanded validation data including knockout confirmation.
5. Technical Challenge and Solution Pathway
Despite Rad23B being a well-characterized target, Rad23B antibodies face a persistent technical hurdle: discrimination from the closely related paralog Rad23A (HR23A) . Rad23A and Rad23B share approximately 70% sequence identity, with both containing UbL and UBA domains and both interacting with XPC and the proteasome. Many commercial antibodies cannot distinguish between the two paralogs, leading to confounding results in expression and interaction studies. A proven solution pathway involves:
- Paralog-specific peptide immunogens: Designing antibodies against unique C-terminal sequences or divergent regions between Rad23A and Rad23B
- Knockout cell line validation: Testing antibody specificity using Rad23B-KO and Rad23A-KO cell lines to confirm paralog-specific detection
- Mass spectrometry confirmation: LC-MS/MS of immunoprecipitated bands to definitively identify whether Rad23A, Rad23B, or both are detected
- RNAi validation: Confirming that siRNA-mediated knockdown of Rad23B (but not Rad23A) reduces antibody signal
- Recombinant protein testing: Testing antibody binding to purified recombinant Rad23A vs. Rad23B by dot blot or ELISA
A 2025 technical note from Journal of Biological Chemistry found that 42% of commercial Rad23B antibodies tested showed detectable cross-reactivity with Rad23A (typically 15-30% of signal), compared to 8% of products from top-tier suppliers (CST, Proteintech, Bethyl) that use paralog-specific validation. The study strongly recommended paralog-specific validation for researchers studying Rad23B in cells expressing both proteins.
6. User Case Example: DNA Repair Mechanistic Study
A university research laboratory in Kyoto, Japan, studying the role of Rad23B in UV-induced DNA damage response faced inconsistent IP results when attempting to co-immunoprecipitate the Rad23B-XPC complex. Using a polyclonal Rad23B antibody from a mid-tier supplier (US310/100µL),thelaboratoryobservedvariableXPCco−IPefficiencyacrossexperiments(CV>35310/100µL),thelaboratoryobservedvariableXPCco−IPefficiencyacrossexperiments(CV>35 445/100 µL) with Rad23B-KO confirmation:
- Rad23A cross-reactivity: Reduced from 28% to <3% (by densitometry of KO cell lysates)
- XPC co-IP consistency: Inter-experiment CV reduced from 38% to 11% across 8 replicates
- UV-induced focus formation: Successfully visualized Rad23B nuclear foci peaking at 4 hours post-UV (25 J/m²) with >90% of cells showing foci
- Publication impact: Manuscript accepted in Genes & Development (impact factor 10) with reviewers specifically commending the paralog-specific validation approach
The laboratory reported that despite the 44% higher unit price, the validated antibody reduced total experiment costs by 31% due to eliminating IP optimization time (saving 4 weeks) and reducing replicate requirements.
7. Market Drivers and Obstacles
Growth drivers include:
- DNA repair research funding: Global DNA repair research spending reached US1.8billionin2025(NIEHS:US1.8billionin2025(NIEHS:US 850 million; European DNA Repair Society; Japanese Society for DNA Repair)
- Ubiquitin-proteasome research expansion: UPS research is central to cancer biology, neurodegeneration, and aging research, with combined funding exceeding US$ 3.2 billion globally
- Cancer biology applications: Rad23B dysregulation in multiple cancer types drives demand for IHC-validated antibodies
- Neurodegenerative disease research: Emerging links between Rad23B and protein aggregation disorders (Parkinson’s, Huntington’s) are expanding the customer base
- Biopharmaceutical industry growth: Increasing penetration of antibody drugs and companion diagnostics creates favorable ecosystem for research reagents
- Regulatory pressure for antibody validation: FDA and EMA guidance on antibody characterization drives demand for well-validated products
Obstacles include:
- Paralog discrimination challenges: High homology with Rad23A complicates antibody specificity validation
- Price sensitivity in academic labs: Especially for early-career researchers and laboratories with constrained funding
- Supplier fragmentation: 18+ suppliers listed in this report, with wide variation in paralog-specific validation quality
- Limited phospho-antibody availability: Few phospho-specific Rad23B antibodies exist, limiting mechanistic studies
8. Regional Outlook
North America leads the Rad23B antibody market (estimated 47% share), driven by NIH funding for DNA repair (NIEHS, NCI) and neurodegeneration (NINDS, NIA), combined with strong biopharmaceutical and cancer research sectors. Europe follows (31% share), with strong DNA repair and UPS research programs in the UK (Francis Crick Institute, University of Dundee), Germany (University of Cologne DNA Repair Center, MPI for Biochemistry), the Netherlands (Erasmus MC), and France (Institut Curie). Asia-Pacific is the fastest-growing region (projected 7.6% CAGR), led by China’s National Natural Science Foundation DNA repair and cancer research funding (¥5.5 billion / US$ 760 million in 2025), Japan’s strong tradition in DNA repair research (Kyoto University, Osaka University), South Korea’s expanding cancer research capabilities, and increasing research investment in Australia and Singapore.
For a complete competitive landscape and regional analysis, the full market report includes breakdowns by North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, plus detailed tables of figures on antibody pricing trends, monoclonal vs. polyclonal adoption rates, paralog-specific validation adoption, and supplier citation rankings in DNA repair and ubiquitin-proteasome literature.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
